Axovant Sciences Announces Public Offering of Common Shares
March 13 2019 - 4:21PM
Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced that it
has commenced an underwritten public offering of its common shares.
All of the common shares are being offered by Axovant. In
connection with this offering, Axovant expects to grant the
underwriters a 30-day option to purchase additional common
shares in the offering on the same terms and conditions.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the offering. The offering is subject to
market conditions, and there can be no assurance as to whether or
when the offering may be completed, or the actual size or terms of
the offering.
A shelf registration statement relating to the offered common
shares was filed with the Securities and Exchange Commission (SEC),
and was declared effective on January 13, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
SEC's website, located at www.sec.gov. Before you
invest, you should read the preliminary prospectus supplement and
accompanying prospectus together with other documents that Axovant
has filed with the SEC for more complete information about Axovant
and the offering. Copies of the preliminary prospectus supplement
and accompanying base prospectus related to the offering may be
obtained, when available, from Jefferies, LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at
Prospectus_Department@Jefferies.com; and Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
New York, NY 10017 or by telephone at (212) 518-5548, or by email
at GSEquityProspectusDelivery@guggenheimpartners.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant Axovant, part of the
Roivant family of companies, is a clinical-stage gene therapy
company focused on developing a pipeline of innovative product
candidates for debilitating neurological and neuromuscular
diseases. The company’s current pipeline of gene therapy candidates
targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs
disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal
muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia. Axovant is focused on accelerating product
candidates into and through clinical trials with a team of experts
in gene therapy development and through external partnerships with
leading gene therapy organizations.
Contacts:
MediaMike BeyerSam Brown Inc. (312)
961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia Truehart(631)
892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024